Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ryvu TherapeuticsLTS:0RKT 66 PS Ratio is 11.08 as of Jul. 16, 2026, which is 43% below its 10-year median of 19.32. GuruFocus rates LTS:0RKT with a GF Score™ of 66/100 and a GF Value™ of zł86.63. The stock has 3 warning signs investors should review. Among 930 Biotechnology companies, Ryvu Therapeutics ranks better than 63.66% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Ryvu Therapeutics's share price is zł30.25.
Ryvu Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was zł2.73. Hence, Ryvu Therapeutics's PS Ratio for today is 11.08.
The historical rank and industry rank for Ryvu Therapeutics's PS Ratio or its related term are showing as below:
LTS:0RKT'
s PS Ratio Range Over the Past 10 Years
Min: 3.9 Med: 19.32 Max: 1188.68
Current: 5.86
During the past 13 years, Ryvu Therapeutics's highest PS Ratio was 1188.68. The lowest was 3.90. And the median was 19.32.
LTS:0RKT's PS Ratio is ranked better than 63.66% of 930
companies
in the Biotechnology industry
Industry Median: 9.655
vs LTS:0RKT: 5.86
Ryvu Therapeutics SA revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Ryvu Therapeutics was -14.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 8.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 35.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -4.30% per year.
During the past 13 years, Ryvu Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 107.40% per year. The lowest was -60.80% per year. And the median was 30.60% per year.
Back to Basics: PS Ratio
Ryvu Therapeutics (LTS:0RKT) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Ryvu Therapeutics PS Ratio Related Terms
Ryvu Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Ryvu Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ryvu Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ryvu Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Ryvu Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Ryvu Therapeutics's Share Price of today is zł30.25. Ryvu Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł2.73.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Ryvu Therapeutics (LTS:0RKT) has a PS Ratio of 11.08 as of Jul. 16, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ryvu Therapeutics and its competitors. This is 43% below median its historical median of 19.32. Over the past decade, Ryvu Therapeutics' PS Ratio has ranged from 3.90 to 1,188.68. According to the industry distribution chart, Ryvu Therapeutics ranks #338 out of 930 companies in the Biotechnology industry, placing it in the top 36.3%.
Is Ryvu Therapeutics' PS Ratio too high?
Ryvu Therapeutics' current PS Ratio of 11.08 is 43% below median its 10-year median of 19.32. Over the past 10 years, this metric has ranged from a low of 3.90 to a high of 1,188.68. The Biotechnology industry median PS Ratio is 9.66. Ryvu Therapeutics' value of 11.08 is 14.8% above this industry median. Based on the distribution chart, Ryvu Therapeutics ranks #338 out of 930 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ryvu Therapeutics has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ryvu Therapeutics ranks #338 out of 930 companies for PS Ratio. This puts Ryvu Therapeutics in the upper half of its industry. The industry median PS Ratio is 9.66. Ryvu Therapeutics' value of 11.08 is 14.8% above this benchmark. Historically, Ryvu Therapeutics' own PS Ratio has ranged from 3.90 to 1,188.68 over the past decade. While the company's 10-year median is 19.32 vs. the industry median of 9.66, Ryvu Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.66, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ryvu Therapeutics's current PS Ratio of 11.08 is 14.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Ryvu Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ryvu Therapeutics's current PS Ratio is 11.08, which is 43% below median its own 10-year median of 19.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Ryvu Therapeutics (LTS:0RKT) has a current PS Ratio of 11.08. The stock's GF Value™ is zł86.63, compared to a current price of zł30.25 — trading 65.1% below its estimated fair value. The current PS Ratio is 11.08, which is 43% below median its 10-year median of 19.32 and 14.8% above the Biotechnology industry median of 9.66. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Ryvu Therapeutics (LTS:0RKT), the current PS Ratio is 11.08 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ryvu Therapeutics (LTS:0RKT) Overvalued in 2026?
Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued.
The current stock price of zł30.25 is trading 65.1% below its estimated GF Value™ of zł86.63.
Key valuation signals for LTS:0RKT:
PS Ratio: 11.08 (43% below median its 10-year median of 19.32)
GF Value™: zł86.63 vs. price of zł30.25 (65.1% below fair value)
Industry Position: 14.8% above the Biotechnology median (#338 of 930)
No single metric tells the full story. See the LTS:0RKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score
Get the complete analysis for LTS:0RKT
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RKT has been successfully added to your 
